You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 11 - 20 of 5486 results
  1. Development of an Effective Strategy to Block Nab Activity for AAV Brain Transduction

    SBC: NABGEN INC            Topic: NCATS

    Adeno-associated virus (AAV) vectors have been successfully employed in patients with rare neurological diseases. Recently, two AAV based gene therapy drugs have been approved by the FDA, Luxturna been valued at $850,000 with a one-time application for blindness and Zolgensma at $2,100,000 for spinal muscle atrophy. AAV vector mediated gene therapy has shown to be a potentially huge market. Althou ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Developing natural compound emodin as a therapy for alcoholic cardiomyopathy

    SBC: AcePre, LLC            Topic: NIAAA

    Project Summary: Alcoholic Cardiomyopathy (ACM) is the most prevalent form of ethanol-induced heart damage. Alcohol dose-dependently induces ACM, characterized by progressive reduction in myocardial contractility and ventricular dilatation, culminating in heart failure. At the cellular level, chronic alcohol consumption results in cardiomyocyte death, cardiac inflammation, and cardiac fibrosis. Th ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Amadorins as a Novel Oral Therapeutic for Diabetic Retinopathy

    SBC: Praetego Inc            Topic: NEI

    PROJECT SUMMARY Diabetic Retinopathy (DR) is a serious diabetic complication that is the leading cause of vision loss in working- age adults, affecting more than 7.5 million people in the USA. It causes more new cases of blindness than any other eye disease in people between the ages of 18 and 65. The anti-VEGF treatments can slow the progress of DR in many patients but are only used after signifi ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Novel Therapeutics for Heart Failure: Modified, Water-Soluble Caveolin-1 Scaffolding Domain Peptides with Improved Characteristics for Drug Development

    SBC: FIBROTHERAPEUTICS INC            Topic: NHLBI

    Abstract Our long-term objective is to fill the unmet need for treatments for heart failure (HF). Caveolin-1 is a promising therapeutic target in fibrotic diseases. The profibrotic effects of caveolin-1 deficiency in cells and in mouse models is suppressed by a peptide equivalent to its active site (caveolin-1 scaffolding domain, CSD). We have shown the beneficial effects of CSD in two independent ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Leptin Receptor Agonist to Treat Sleep Disordered Breathing

    SBC: Arrevus, Inc.            Topic: NHLBI

    PROJECT SUMMARY/ABSTRACT Obstructive sleep apnea (OSA) and obesity hypoventilation syndrome (OHS) are the most common types of sleep disordered breathing (SDB). OSA is highly prevalent in the United States, affecting 20-40% of the adult population and more than 50% of individuals with obesity. Approximately 20% of individuals with obesity develop OHS defined as daytime hypercapnia and hypoventilat ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Preclinical Development of a Novel Therapeutic Agent for Idiopathic Pulmonary Fibrosis

    SBC: FibroBiologics, LLC            Topic: NHLBI

    Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease with a median survival of only 3 - 5 years from diagnosis. Although two FDA-approved drugs, pirfenidone and nintedanib, may slow the rate of decline of lung function in some IPF patients, neither drug significantly alters the course of this lethal disease. There is a great need for new drugs with greater efficacy and le ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Developing novel LOX inhibitors to target chemotherapy resistant TNBC

    SBC: LOXIGEN, INC.            Topic: 102

    PROJECT SUMMARY Triple negative breast cancer (TNBC) is the most aggressive breast cancer subtype. It accounts for ~15% of all breast cancer yet is responsible for 30% of breast cancer deaths. TNBC is treated primarily by conventional chemotherapy; however, resistance to therapy is common, leading to high mortality rates. Importantly, the benefit of current therapeutic strategies used in chemoresi ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Digital clinical hypnosis for chronic pain management

    SBC: HYPNOSCIENTIFIC, INC.            Topic: R

    Project Summary Chronic pain is a prevalent, disabling problem affecting as many as 116 million adults in the United States. However, there are very few treatment options for chronic pain management, and those that are available are inadequate for the majority of those with this condition. Many also have significant negative side effects or are associated with significant adverse events. A growing ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Improved Treatment of Colorectal Cancer with CF10

    SBC: Deep Creek Pharma, LLC            Topic: 102

    PROJECT SUMMARY Decades of modulating the anti-cancer activity of fluoropyrimidine drugs (FPs) thru schedule optimization, biochemical modulation, and drug combinations have provided a significant, but limited, survival advantage for treating colorectal cancer (CRC) patients with locally advanced or metastatic disease (mCRC). However, outcomes remain poor for patients with mCRC and since targeted ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Novel Small Molecule Drug Candidate for the Prevention of Bronchopulmonary Dysplasia

    SBC: CMTX BIOTECH, INC.            Topic: NICHD

    PROJECT SUMMARY/ABSTRACT CMTx Biotech is a drug development company working to commercialize a proprietary, clinical-stage, small- molecule drug candidate for the prevention of respiratory distress syndrome (RDS) and its long-term sequelae, bronchopulmonary dysplasia (BPD), in preterm infants. BPD is a chronic respiratory disease that occurs in preterm infants who develop RDS from a combination of ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government